<DOC>
	<DOC>NCT00238979</DOC>
	<brief_summary>The aim of this study is whether a switch of stable renal transplant recipients who receive tacrolimus with or without corticosteroids from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPS) is safe and well tolerated by the patients.</brief_summary>
	<brief_title>A Study to Investigate the Tolerability and Safety of Converting Stable Renal Transplant Recipients Who Receive Tacrolimus With or Without Corticosteroids From Mycophenolate Mofetil (MMF) to Enteric-coated Mycophenolate Sodium (EC-MPS)</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Inclusion criteria: Recipients of first or secondary cadaveric heartbeating, living unrelated or living related kidney transplant. Currently receiving 1, 1.5, or 2 g MMF/day, tacrolimus with or without corticosteroids as part of their immunosuppressive regimen for at least 3 months. In a stable condition in terms of graft function. Exclusion criteria: Patients who had taken an investigational drug within four weeks prior to study entry History of malignancy within the last 5 years, except excised squamous or basal cell carcinoma of the skin. Thrombocytopenia (&lt;75,000/mm3), with an absolute neutrophil count of &lt;1,500/mm3 and/or leukocytopenia (&lt;2,500/mm3), and/or hemoglobin &lt;6.0 g/dL prior to enrollment Clinically significant infection requiring continued therapy, severe diarrhea, active peptic ulcer disease, or uncontrolled diabetes mellitus, evidence of severe liver disease, HIV or Hepatitis B surface antigen positive. Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Renal transplantation, Enteric-coated mycophenolate sodium</keyword>
</DOC>